Prostate Cancer - Results from #1820

Recruitment Target Achieved for Phase II SAR-Bombesin Prostate Cancer Trial November 7, 2023

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radioligand Therapy. November 7, 2023

Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand? November 7, 2023

Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry. November 7, 2023

Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages-dependence on GPR120. November 7, 2023

Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate. November 7, 2023

Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial. November 7, 2023

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. November 7, 2023

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. November 7, 2023

Personalized Medicine for Metastatic Prostate Cancer: The Paradigm of PARP Inhibitors. November 7, 2023

Understanding Current Demographics, Practice Patterns, and Concerns of Women in Urology: Analysis From the 2022 Society of Women in Urology Census Task Force November 6, 2023

New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer November 6, 2023

Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. November 6, 2023

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. November 6, 2023

Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. November 6, 2023

Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers. November 6, 2023

Heterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa. November 6, 2023

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. November 6, 2023

MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis. November 6, 2023

Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption. November 6, 2023

Page 92 of 1435